{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:25:22Z","timestamp":1784895922167,"version":"3.55.0"},"reference-count":8,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most pressing public health challenges, affecting more than 30% of the global adult population and projected to exceed 55% prevalence by 2040 [...]<\/jats:p>","DOI":"10.3390\/life16060915","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:37:29Z","timestamp":1780544249000},"page":"915","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6743-8942","authenticated-orcid":false,"given":"Ioannis","family":"Katsaros","sequence":"first","affiliation":[{"name":"First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0112","authenticated-orcid":false,"given":"Dimitrios","family":"Schizas","sequence":"additional","affiliation":[{"name":"First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Karavia, E.A., Pittaras, A., Andreopoulou, O., Hatziri, A., Makrydimitri, A., Anagnostopoulos, D., Vareltzis, P., and Kypreos, K.E. (2026). Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies. Pharmaceuticals, 19.","DOI":"10.3390\/ph19040605"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rotaru, A., Stafie, R., Stratina, E., Zenovia, S., Nastasa, R., Minea, H., Huiban, L., Cuciureanu, T., Muzica, C., and Chiriac, S. (2025). Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut\u2013Liver Axis. Life, 15.","DOI":"10.3390\/life15020288"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Scarlata, G.G.M., and Abenavoli, L. (2025). Comment on Rotaru et al. Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut\u2013Liver Axis. Life 2025, 15, 288. Life, 15.","DOI":"10.3390\/life15081210"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ozlu Karahan, T., Yilmaz Akyuz, E., Yilmaz Karadag, D., Yilmaz, Y., and Eren, F. (2025). Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. Life, 15.","DOI":"10.3390\/life15050696"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sotiropoulou, M., Katsaros, I., Vailas, M., Papachristou, F., Papakyriakopoulou, P., Kostomitsopoulos, N., Giatromanolaki, A., Valsami, G., Tsaroucha, A., and Schizas, D. (2025). Therapeutic Potential of Quercetin, Silibinin, and Crocetin in a High-Fat Diet-Induced Mouse Model of MASLD: The Role of CD36 and PLIN3. Life, 15.","DOI":"10.3390\/life15101523"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Suarez, B., \u00c1lvarez, A.M., Mascardi, M.F., Ramos, A.L.M., Woo, D.H., Guti\u00e9rrez, M.M., Alzueta, G., Basbus, M.D.C., Bruzone, S., and Cuart, P. (2026). Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina. Life, 16.","DOI":"10.3390\/life16020283"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/915\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:08:46Z","timestamp":1780546126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":8,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16060915"],"URL":"https:\/\/doi.org\/10.3390\/life16060915","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}